|
News / Articles
NEW YORK (MarketWatch) -- The U.S. Food and Drug Administration has asked
Pfizer (PFE)
to withdraw its arthritis pain reliever Bextra from the market, due to an
unfavorable benefit vs. risk profile. The FDA also asked the drugmaker to
add a warning on its painkiller Celebrex about an increased risk of
cardiovascular and gastrointestinal events. Pfizer's stock, a component of
the Dow industrials, fell 4.2% to $25.73 in Instinet pre-open trading. All
other makers of non-steroidal anti-inflammatory drugs were asked to revise
their labels to add the same warning.
|
